IL110296A - Imidazole compounds process for their preparation and pharmaceutical compositions containing them - Google Patents

Imidazole compounds process for their preparation and pharmaceutical compositions containing them

Info

Publication number
IL110296A
IL110296A IL11029694A IL11029694A IL110296A IL 110296 A IL110296 A IL 110296A IL 11029694 A IL11029694 A IL 11029694A IL 11029694 A IL11029694 A IL 11029694A IL 110296 A IL110296 A IL 110296A
Authority
IL
Israel
Prior art keywords
preparation
pharmaceutical compositions
compositions containing
imidazole compounds
compounds process
Prior art date
Application number
IL11029694A
Other languages
English (en)
Other versions
IL110296A0 (en
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of IL110296A0 publication Critical patent/IL110296A0/xx
Publication of IL110296A publication Critical patent/IL110296A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
IL11029694A 1993-07-16 1994-07-12 Imidazole compounds process for their preparation and pharmaceutical compositions containing them IL110296A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9273393A 1993-07-16 1993-07-16

Publications (2)

Publication Number Publication Date
IL110296A0 IL110296A0 (en) 1994-10-21
IL110296A true IL110296A (en) 1999-12-31

Family

ID=22234840

Family Applications (2)

Application Number Title Priority Date Filing Date
IL11029694A IL110296A (en) 1993-07-16 1994-07-12 Imidazole compounds process for their preparation and pharmaceutical compositions containing them
IL12431898A IL124318A0 (en) 1993-07-16 1998-05-04 Starting material for the preparation of imidazole compounds

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL12431898A IL124318A0 (en) 1993-07-16 1998-05-04 Starting material for the preparation of imidazole compounds

Country Status (31)

Country Link
EP (5) EP1291346B1 (fr)
JP (4) JPH09500137A (fr)
CN (2) CN1050126C (fr)
AP (1) AP484A (fr)
AT (2) ATE236896T1 (fr)
AU (1) AU694130C (fr)
BR (2) BR9407079A (fr)
CA (1) CA2167311A1 (fr)
CZ (1) CZ11996A3 (fr)
DE (2) DE69432463T2 (fr)
DK (1) DK0708768T3 (fr)
DZ (1) DZ1798A1 (fr)
ES (2) ES2237650T3 (fr)
FI (1) FI960177A0 (fr)
HK (3) HK1049658A1 (fr)
HU (1) HUT75313A (fr)
IL (2) IL110296A (fr)
MA (1) MA23270A1 (fr)
MY (1) MY116478A (fr)
NO (4) NO316881B1 (fr)
NZ (2) NZ329994A (fr)
PL (4) PL181721B1 (fr)
PT (1) PT708768E (fr)
RU (1) RU2140918C1 (fr)
SG (1) SG52368A1 (fr)
SI (1) SI0708768T1 (fr)
SK (1) SK282342B6 (fr)
TW (1) TW330934B (fr)
UA (1) UA63875C2 (fr)
WO (1) WO1995002591A1 (fr)
ZA (1) ZA945193B (fr)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3857751A (en) * 1971-11-15 1974-12-31 Tufdura Ltd Composite sheet capable of withstanding impingement by particulate materials
US5916891A (en) 1992-01-13 1999-06-29 Smithkline Beecham Corporation Pyrimidinyl imidazoles
US5840746A (en) * 1993-06-24 1998-11-24 Merck Frosst Canada, Inc. Use of inhibitors of cyclooxygenase in the treatment of neurodegenerative diseases
US5593992A (en) * 1993-07-16 1997-01-14 Smithkline Beecham Corporation Compounds
US5670527A (en) * 1993-07-16 1997-09-23 Smithkline Beecham Corporation Pyridyl imidazole compounds and compositions
US5616601A (en) * 1994-07-28 1997-04-01 Gd Searle & Co 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation
US6613789B2 (en) 1994-07-28 2003-09-02 G. D. Searle & Co. Heterocyclo-substituted imidazoles for the treatment of inflammation
FI972970A7 (fi) * 1995-01-12 1997-09-11 Smithkline Beecham Corp Uusia yhdisteitä
GB9500580D0 (en) * 1995-01-12 1995-03-01 Merck Sharp & Dohme Therapeutic agents
EP0809492A4 (fr) * 1995-02-17 2007-01-24 Smithkline Beecham Corp Antagonistes des recepteurs d'il-8
US6369068B1 (en) 1995-06-07 2002-04-09 Smithkline Beecham Corporation Amino substituted pyrimidine containing compounds
IL118544A (en) 1995-06-07 2001-08-08 Smithkline Beecham Corp History of imidazole, the process for their preparation and the pharmaceutical preparations containing them
US5739143A (en) * 1995-06-07 1998-04-14 Smithkline Beecham Corporation Imidazole compounds and compositions
US6083949A (en) * 1995-10-06 2000-07-04 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
US5717100A (en) * 1995-10-06 1998-02-10 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
DE19540027A1 (de) * 1995-10-27 1997-04-30 Gruenenthal Gmbh Substituierte Imidazolidin-2,4-dion-Verbindungen als pharmazeutische Wirkstoffe
ZA9610687B (en) * 1995-12-22 1997-09-29 Smithkline Beecham Corp Novel synthesis.
WO1997025047A1 (fr) * 1996-01-11 1997-07-17 Smithkline Beecham Corporation Nouveaux imidazoles cycloalkyle-substitues
US6046208A (en) * 1996-01-11 2000-04-04 Smithkline Beecham Corporation Substituted imidazole compounds
ZA97175B (en) * 1996-01-11 1997-11-04 Smithkline Beecham Corp Novel substituted imidazole compounds.
PL187516B1 (pl) * 1996-01-11 2004-07-30 Smithkline Beecham Corp Nowe podstawione pochodne imidazolu, sposób ich wytwarzania oraz kompozycja farmaceutyczna zawierająca te związki
AP9700912A0 (en) 1996-01-11 1997-01-31 Smithkline Beecham Corp Novel cycloalkyl substituted imidazoles
WO1997032583A1 (fr) * 1996-03-08 1997-09-12 Smithkline Beecham Corporation Utilisations de composes csaidtm en tant qu'inhibiteurs de l'angiogenese
JP2000507558A (ja) * 1996-03-25 2000-06-20 スミスクライン・ビーチャム・コーポレイション Ｃｎｓ損傷についての新規な治療
EP0906307B1 (fr) * 1996-06-10 2005-04-27 Merck & Co., Inc. Imidazoles substitues inhibant la cytokine
WO1998007425A1 (fr) 1996-08-21 1998-02-26 Smithkline Beecham Corporation Composes d'imidazole, compositions les contenant et leur utilisation
US5945418A (en) * 1996-12-18 1999-08-31 Vertex Pharmaceuticals Incorporated Inhibitors of p38
US6608060B1 (en) 1996-12-18 2003-08-19 Vertex Pharmaceuticals Incorporated Inhibitors of p38
US6147080A (en) * 1996-12-18 2000-11-14 Vertex Pharmaceuticals Incorporated Inhibitors of p38
US5929076A (en) * 1997-01-10 1999-07-27 Smithkline Beecham Corporation Cycloalkyl substituted imidazoles
US6187799B1 (en) 1997-05-23 2001-02-13 Onyx Pharmaceuticals Inhibition of raf kinase activity using aryl ureas
CA2294057A1 (fr) 1997-06-13 1998-12-17 Smithkline Beecham Corporation Nouveaux composes de pyrazole et de pyrazoline substitues
AU8154998A (en) 1997-06-19 1999-01-04 Smithkline Beecham Corporation Novel aryloxy substituted pyrimidine imidazole compounds
US7301021B2 (en) 1997-07-02 2007-11-27 Smithkline Beecham Corporation Substituted imidazole compounds
US6489325B1 (en) 1998-07-01 2002-12-03 Smithkline Beecham Corporation Substituted imidazole compounds
TW517055B (en) * 1997-07-02 2003-01-11 Smithkline Beecham Corp Novel substituted imidazole compounds
WO1999001452A1 (fr) 1997-07-02 1999-01-14 Smithkline Beecham Corporation Nouveaux imidazoles cycloalkyle-substitues
US6562832B1 (en) 1997-07-02 2003-05-13 Smithkline Beecham Corporation Substituted imidazole compounds
WO1999017776A1 (fr) 1997-10-08 1999-04-15 Smithkline Beecham Corporation Nouveaux composes substitues de cycloalcenyle
EP1021173A1 (fr) * 1997-10-10 2000-07-26 Imperial College Innovations Limited Emploi de composes de csaid?tm pour le traitement des contractions uterines
JP3337992B2 (ja) * 1997-11-04 2002-10-28 ファイザー製薬株式会社 ５−置換ピコリン酸化合物及びその製造方法
WO1999032121A1 (fr) * 1997-12-19 1999-07-01 Smithkline Beecham Corporation .0mposes d'imidazole heteroaryle substitues, leurs compositions et usages pharmaceutiques
US7517880B2 (en) 1997-12-22 2009-04-14 Bayer Pharmaceuticals Corporation Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
US7329670B1 (en) 1997-12-22 2008-02-12 Bayer Pharmaceuticals Corporation Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas
GB9809869D0 (en) * 1998-05-09 1998-07-08 Medical Res Council Inhibition of protein kinases
CN1548436A (zh) 1998-05-22 2004-11-24 ʷ��˿�������ȳ�ķ���޹�˾ 新的2-烷基取代咪唑化合物
US6858617B2 (en) 1998-05-26 2005-02-22 Smithkline Beecham Corporation Substituted imidazole compounds
EP1109918B1 (fr) 1998-06-24 2006-10-04 University of Dundee Proteine kinases activees par des signaux mitogenes et le stress comprenant deux domaines kinase et leurs utilisations
WO2000001688A1 (fr) * 1998-07-02 2000-01-13 Sankyo Company, Limited Composes heteroaryle a cinq elements
US6207687B1 (en) * 1998-07-31 2001-03-27 Merck & Co., Inc. Substituted imidazoles having cytokine inhibitory activity
JP2003525201A (ja) * 1998-08-20 2003-08-26 スミスクライン・ビーチャム・コーポレイション 新規な置換トリアゾール化合物
WO2000025791A1 (fr) 1998-11-04 2000-05-11 Smithkline Beecham Corporation Pyrazines substitues pyridin-4-yle ou pyrimidin-4-yle
US6239279B1 (en) 1998-12-16 2001-05-29 Smithkline Beecham Corporation Synthesis for 4-aryl-5-pyrimidine imidazole substituted derivatives
ATE538794T1 (de) 1999-01-13 2012-01-15 Bayer Healthcare Llc Gamma carboxyarylsubstituierte diphenylharnstoffverbindungen als p38 kinasehemmer
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7351834B1 (en) 1999-01-13 2008-04-01 Bayer Pharmaceuticals Corporation ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US20020065296A1 (en) 1999-01-13 2002-05-30 Bayer Corporation Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors
WO2000042012A1 (fr) 1999-01-13 2000-07-20 Bayer Corporation DIPHENYLUREES A SUBSTITUANTS φ-CARBOXYARYLES, INHIBITRICES DE KINASE RAF
US7122666B2 (en) 1999-07-21 2006-10-17 Sankyo Company, Limited Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses
ATE305787T1 (de) 1999-11-23 2005-10-15 Smithkline Beecham Corp 3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p39-kinase-inhibitoren
US6759410B1 (en) 1999-11-23 2004-07-06 Smithline Beecham Corporation 3,4-dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors
AU1781601A (en) 1999-11-23 2001-06-04 Smithkline Beecham Corporation 3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p38 kinase inhibitors
EP1233951B1 (fr) 1999-11-23 2005-06-01 SmithKline Beecham Corporation Composes de 3,4-dihydro-(1h)quinazolin-2-one utilises comme inhibiteurs de kinase csbp/p38
US7235551B2 (en) 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
US6627647B1 (en) 2000-03-23 2003-09-30 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted 1-(4-aminophenyl)imidazoles and their use as anti-inflammatory agents
GB0021726D0 (en) * 2000-09-05 2000-10-18 Astrazeneca Ab Chemical compounds
US7235576B1 (en) 2001-01-12 2007-06-26 Bayer Pharmaceuticals Corporation Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
ITMI20010206A1 (it) * 2001-02-02 2002-08-02 Dompe Spa Uso della metansolfonammide di (r)-ibuprofene e dei suoi sali non tossici per la preparazione di medicamenti per il trattamento e la prevenz
US7371763B2 (en) 2001-04-20 2008-05-13 Bayer Pharmaceuticals Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
FR2823747B1 (fr) * 2001-04-24 2003-05-23 Oreal Nouveaux composes de la famille des 3-alkyl-(4,5 diphenyl- imidazol-1-yl) et leur utilisation comme anti-inflammatoires
FR2823751B1 (fr) * 2001-04-24 2003-05-23 Oreal Nouveaux composes de la famille des 3-alkyl-(4,5 diphenyl- imidazol-1-yl) et leur utilisation comme anti-inflammatoires
WO2002094267A1 (fr) * 2001-05-24 2002-11-28 Sankyo Company, Limited Preparation pharmaceutique pour prevenir ou traiter l'arthrite
MXPA04007832A (es) 2002-02-11 2005-09-08 Bayer Pharmaceuticals Corp Aril-ureas con actividad inhibitoria de angiogenesis.
MXPA04007830A (es) 2002-02-11 2005-07-01 Bayer Pharmaceuticals Corp Arilureas como inhibidores de cinasa.
RU2217196C2 (ru) * 2002-02-28 2003-11-27 Небольсин Владимир Евгеньевич Способ индукции дифференцировки клеток
JP4481011B2 (ja) 2002-03-05 2010-06-16 トランス テック ファーマ，インコーポレイテッド リガンドのｒａｇｅとの相互作用を阻害する単環式および二環式アゾール誘導体
AR039241A1 (es) 2002-04-04 2005-02-16 Biogen Inc Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
EP1499305A2 (fr) * 2002-04-12 2005-01-26 Pfizer Japan Inc. Utilisation de ligands du recepteur ep4 dans le traitement de maladies impliquant il-6
ATE479683T1 (de) 2002-11-05 2010-09-15 Glaxo Group Ltd Antibakterielle mittel
WO2004113274A2 (fr) 2003-05-20 2004-12-29 Bayer Pharmaceuticals Corporation Diaryl-urees presentant une activite d'inhibition des kinases
EA010485B1 (ru) 2003-07-23 2008-10-30 Байер Фамэсьютиклс Копэрейшн Производное n,n'-дифенилмочевины, фармацевтическая композиция (варианты) и способ лечения и предупреждения заболеваний и состояний с его использованием (варианты)
TWI381841B (zh) * 2005-03-11 2013-01-11 Zenyaku Kogyo Kk An immunosuppressive agent and an antitumor agent containing a heterocyclic compound as an active ingredient
CN101137656B (zh) * 2005-03-11 2010-12-22 拉夸里亚创药株式会社 咪唑衍生物的晶型
RU2297839C1 (ru) * 2005-10-10 2007-04-27 Всероссийский научно-исследовательский институт пантового оленеводства (ВНИИПО) Лекарственное средство для лечения актиномикоза
ES2467923T3 (es) 2009-09-30 2014-06-13 Transtech Pharma, Llc Derivados de imidazol substituidos para el tratamiento de la enfermedad de Alzheimer
SI2493876T1 (sl) 2009-10-28 2014-04-30 Pfizer Inc. Derivati imidazola kot inhibitorji kazein-kinaze
RU2418582C1 (ru) * 2010-04-08 2011-05-20 Аверин Константин Михайлович 1,3-диалкилбензимидазолия галогениды - средства для лечения рассеянного склероза
CN104387301B (zh) * 2014-11-11 2016-05-04 常州大学 一种2-氟-4-甲基苯磺酰甲基异腈的合成方法
CN107847480B (zh) 2015-03-23 2021-06-25 墨尔本大学 呼吸性疾病的治疗
PT3619204T (pt) * 2017-05-03 2025-10-29 Tianli Biotech Pty Ltd Compostos para o tratamento de doenças respiratórias
JP7575099B2 (ja) 2018-11-07 2024-10-29 ティアンリ バイオテック プロプライエタリ リミテッド 呼吸器疾患の処理のための新規な化合物
CN110531023B (zh) * 2019-10-08 2024-06-14 安徽理工大学 一种薄层色谱分析仪
CN114112812B (zh) * 2021-10-29 2024-05-24 华北电力大学 相变颗粒测试装置、固-液相变机理可视化实验台及方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3707475A (en) * 1970-11-16 1972-12-26 Pfizer Antiinflammatory imidazoles
US3929807A (en) * 1971-05-10 1975-12-30 Ciba Geigy Corp 2-Substituted-4(5)-(aryl)-5(4)-(2,3 or -4-pyridyl)-imidazoles
DE2242454A1 (de) * 1972-08-29 1974-03-07 Bayer Ag 1-aethyl-imidazole, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
IL95880A (en) * 1989-10-13 1995-12-31 Pfizer Use of 3-Transformed History of 2-Oxindole for the Preparation of Pharmaceuticals for Inhibition of Interlaukio-1 Biosynthesis
JPH06504779A (ja) * 1990-12-13 1994-06-02 スミスクライン・ビーチャム・コーポレイション 新規ｃｓａｉｄｓ
IE914327A1 (en) * 1990-12-13 1992-06-17 Smithkline Beecham Corp Novel csaids
MX9300141A (es) * 1992-01-13 1994-07-29 Smithkline Beecham Corp Compuestos de imidazol novedosos, procedimiento para su preparacion y composiciones farmaceuticas que lo contienen.

Also Published As

Publication number Publication date
AU694130B2 (en) 1998-07-16
DZ1798A1 (fr) 2002-02-17
EP0708768B1 (fr) 2003-04-09
DE69432463D1 (de) 2003-05-15
WO1995002591A1 (fr) 1995-01-26
NO10837A (no) 1996-01-15
EP1227091A2 (fr) 2002-07-31
CN1129447A (zh) 1996-08-21
TW330934B (en) 1998-05-01
NO20010837D0 (no) 2001-02-19
AP484A (en) 1996-04-23
ZA945193B (en) 1995-04-20
NO316881B1 (no) 2004-06-14
SI0708768T1 (en) 2003-10-31
AU705568B2 (en) 1999-05-27
DE69434316D1 (de) 2005-04-28
NO960173L (no) 1996-01-15
DE69432463T2 (de) 2004-02-12
JP2004083600A (ja) 2004-03-18
PL312614A1 (en) 1996-04-29
CZ11996A3 (en) 1996-10-16
FI960177L (fi) 1996-01-15
UA63875C2 (en) 2004-02-16
EP1227092A3 (fr) 2002-08-07
RU2140918C1 (ru) 1999-11-10
ES2237650T3 (es) 2005-08-01
NO20010839D0 (no) 2001-02-19
JPH09500137A (ja) 1997-01-07
NO20010838D0 (no) 2001-02-19
AU7185098A (en) 1998-08-27
SK282342B6 (sk) 2002-01-07
PL181705B1 (pl) 2001-09-28
NO10839A (no) 1996-01-15
NZ329994A (en) 1999-07-29
DK0708768T3 (da) 2003-08-04
HK1012392A1 (en) 1999-07-30
CA2167311A1 (fr) 1995-01-26
EP0708768A1 (fr) 1996-05-01
EP1227092A2 (fr) 2002-07-31
JP2004099622A (ja) 2004-04-02
SK4796A3 (en) 1997-01-08
PT708768E (pt) 2003-08-29
FI960177A7 (fi) 1996-01-15
AU694130C (en) 2002-12-05
EP1291346B1 (fr) 2005-03-23
AP9400654A0 (en) 1994-07-31
ATE291576T1 (de) 2005-04-15
NZ269457A (en) 1998-08-26
HK1049659A1 (en) 2003-05-23
IL110296A0 (en) 1994-10-21
NO960173D0 (no) 1996-01-15
FI960177A0 (fi) 1996-01-15
PL181723B1 (pl) 2001-09-28
HK1049658A1 (en) 2003-05-23
MY116478A (en) 2004-02-28
CN1218801A (zh) 1999-06-09
EP0708768A4 (fr) 1996-08-21
HUT75313A (en) 1997-05-28
MA23270A1 (fr) 1995-04-01
AU7335494A (en) 1995-02-13
PL181721B1 (en) 2001-09-28
HU9503855D0 (en) 1996-02-28
BR9407079A (pt) 1996-08-27
EP1291346A1 (fr) 2003-03-12
NO10838A (no) 1996-01-15
EP1229035A1 (fr) 2002-08-07
ES2197167T3 (es) 2004-01-01
BR1100546A (pt) 2004-08-31
PL181694B1 (pl) 2001-09-28
ATE236896T1 (de) 2003-04-15
SG52368A1 (en) 1998-09-28
CN1050126C (zh) 2000-03-08
DE69434316T2 (de) 2006-03-09
JP2004149541A (ja) 2004-05-27
EP1227091A3 (fr) 2002-08-07
HK1049657A1 (en) 2003-05-23
IL124318A0 (en) 1998-12-06

Similar Documents

Publication Publication Date Title
IL110296A (en) Imidazole compounds process for their preparation and pharmaceutical compositions containing them
IL116455A0 (en) Imidazole compounds and pharmaceutical compositions containing them
HUT64734A (en) Anthraquinone-derivativdes, process for preparing them and pharmaceutical compositions containing them
IL105220A0 (en) Cyclohexanylidene compounds and pharmaceutical compositions containing them
IL122618A0 (en) Substituted imidazolylacetonitrile compounds their preparation and pharmaceutical compositions containing them
HUT59677A (en) Process for producing indol- and benzimidazol-substituted imidazol deivatives and pharmaceutical compositions containing them
IL122717A0 (en) Compounds and pharmaceutical compositions containing them
ZA934090B (en) Biphenyl derivatives pharmaceutical compositions containing these compounds and processes for preparing them
HUT69712A (en) Process for preparing benzimidazole derivatives and pharmaceutical compositions containing them
ZA952046B (en) Benzimidazoles pharmaceutical compositions containing these compounds and processes for preparing them
IL115072A (en) Pharmaceutical compositions containing substituted 4-phenyl-6-amino-nicotinic acid derivatives their preparation some such new compounds and process for their preparation
IL117620A0 (en) Heterocyclic compounds processes for the preparation thereof and pharmaceutical compositions containing the same
SG43083A1 (en) Benzinidaziles pharmaceutical compositions containing these compounds and processes for preparing them
IL111011A0 (en) Bisbenzimidazole compounds, their preparation and pharmaceutical compositions containing them
HU9402187D0 (en) Heterocyclic compounds, process for producing them and pharmaceutical compositions containing them
ZA9511029B (en) Substituted 4-phenylthiazole derivatives process for their preparation and pharmaceutical compositions containing them
ZA945597B (en) Methyiguanidine derivatives process for their preparation and the compositions containing them
IL106385A0 (en) Heterocyclic compounds,their preparation and pharmaceutical compositions containing them
ZA941088B (en) Substituted ketophosphonates the processes for their preparation and pharmaceutical compositions containing them
HUT72319A (en) Epoxy-succinic acid derivatives, pharmaceutical compositions containing them and process for their preparation
HUP9601680A3 (en) Benzisothiazolyl-substituted aminomethyl-chromanes, pharmaceutical compositions containing the same, process for their preparation and use of the compounds
IL104471A0 (en) Imidazole derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same
ZA966154B (en) Aminophenylphosphonic acid compounds process for preparing them and pharmaceutical compositions containing them
ZA963350B (en) Cycloheaxane compounds process for their preparation and pharmaceutical compositions containing them
ZA933638B (en) Heterocyclic compounds a process for the preparation thereof and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
FF Patent granted
MM9K Patent not in force due to non-payment of renewal fees